Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics

Current strategies to treat tuberculosis (TB) and co-morbidities involve multidrug combination therapies. Rifamycin antibiotics are a key component of TB therapy and a common source of drug–drug interactions (DDIs) due to induction of drug metabolizing enzymes (DMEs). Management of rifamycin DDIs ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Dyavar, Shetty Ravi, Mykris, Timothy M., Winchester, Lee C., Scarsi, Kimberly K., Fletcher, Courtney V., Podany, Anthony T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387492/
https://www.ncbi.nlm.nih.gov/pubmed/32724080
http://dx.doi.org/10.1038/s41598-020-69228-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387492/
https://www.ncbi.nlm.nih.gov/pubmed/32724080
http://dx.doi.org/10.1038/s41598-020-69228-z

Ejemplares similares